The Lynx Group

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

The first-line immunotherapy combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) continues to show robust, durable clinical benefit, with a deepening of response, in patients with microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), according to results presented at the ASCO 2020 virtual annual meeting.
Read More

Interim analysis of the phase 3 JAVELIN Bladder 100 clinical trial showed that maintenance therapy with the PD-L1 inhibitor avelumab (Bavencio) plus best supportive care significantly prolonged overall survival (OS) versus best supportive care alone in patients with advanced urothelial carcinoma whose disease did not progress with first-line platinum-based chemotherapy.
Read More

Targeted therapy with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence), which is currently approved for the treatment of patients with non-Hodgkin lymphoma, has demonstrated durable remissions in treatment-naïve patients with chronic lymphocytic leukemia (CLL), according to the long-term data from the phase 2 CLL-001 study, which were presented at the ASCO 2020 virtual annual meeting.
Read More

“COVID-19 has been like a 9/11 moment in healthcare,” said Michael Kolodziej, MD, Senior Advisor, ADVI Health, at the Association for Value-Based Cancer Care (AVBCC) July 28, 2020, webcast. “We don’t have a playbook. It’s required us to rethink.”
Read More

Early results from the phase 2 TheraP clinical trial show that the targeted radiation therapy Lutetium-177 PSMA-617 (Lu-PSMA) significantly improved prostate-specific antigen (PSA) response compared with standard cabazitaxel in men with metastatic castration-resistant prostate cancer (CRPC) that progressed after docetaxel therapy.
Read More

Adjuvant therapy with atezolizumab (Tecentriq) did not meet the primary end point of disease-free survival (DFS) in patients with muscle-invasive urothelial cancer (MIUC) at high risk for recurrence versus observation alone in the primary analysis of the IMvigor010 trial.
Read More

A total of 80% of patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) achieved a complete response (CR) to axicabtagene ciloleucel (Yescarta), and those responses have proved durable, according to the interim results of the phase 2 ZUMA-5 study, said Caron A. Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting.
Read More

According to long-term follow-up data presented at the ASCO 2020 annual meeting, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has demonstrated ongoing durable remissions lasting up to 113 months for follicular lymphoma, 99 months for chronic lymphocytic leukemia (CLL), and 97 months for diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL).
Read More

Since March 2020, Cancer Support Community has broken records for the number of calls coming into its national network, said Elizabeth Franklin, LGSW, ACSW, Executive Director of the Cancer Policy Institute and Co-Chair of the Policy and Advocacy Committee of the Academy of Oncology Nurse & Patient Navigators (AONN+), in a webinar of the Association for Value-Based Cancer Care (AVBCC) on COVID-19.
Read More

With new cancer diagnoses down by 37% since the onset of the COVID-19 pandemic, and data from IQVIA showing that 22 million people postponed cancer screening tests and 80,000 patients delayed or missed diagnoses, America’s comprehensive cancer centers and integrated delivery networks (IDNs) are anticipating a major “shadow curve” in new cancer cases in the months and year to come.
Read More

Page 3 of 3

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: